Thompson Siegel & Walmsley’s Haemonetics HAE Stock Holding History

Thompson Siegel & Walmsley’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,000	Closed	-$572K	–	405
2025 Q1	$572K	Buy	+9,000	New	+$612K	0.01%	326
2023 Q1	–	Sell	-22	Closed	-$2K	–	561
2022 Q4	$2K	Sell	22 -173,268	-100%	-$13.9M	﹤0.01%	525
2022 Q3	$12.8M	Sell	173,290 -69,723	-29%	-$5.01M	0.22%	113
2022 Q2	$15.8M	Sell	243,013 -36,129	-13%	-$2.14M	0.25%	104
2022 Q1	$17.6M	Sell	279,142 -9,731	-3%	-$529K	0.25%	106
2021 Q4	$15.3M	Buy	288,873 +47,110	+19%	+$2.87M	0.21%	118
2021 Q3	$17.1M	Sell	241,763 -78,650	-25%	-$4.96M	0.25%	104
2021 Q2	$21.4M	Buy	+320,413	New	+$22.7M	0.29%	92
2017 Q1	–	Sell	-60	Closed	-$2K	–	894
2016 Q4	$2K	Buy	+60	New	+$2.26K	﹤0.01%	773

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Thompson Siegel & Walmsley's HAE Position: Q2 2025 in Review

Thompson Siegel & Walmsley sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 9,000 shares — an estimated $572K sold.

Thompson Siegel & Walmsley first reported a position in HAE in Q4 2016 and held it in 9 quarters. The position peaked at $21.4M in Q2 2021. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

Thompson Siegel & Walmsley reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
Thompson Siegel & Walmsley sold 9,000 Haemonetics shares in Q2 2025, an estimated $572K.
Thompson Siegel & Walmsley first reported a position in Haemonetics in Q4 2016 and held it in 9 quarters.
Thompson Siegel & Walmsley's Haemonetics position peaked at $21.4M in Q2 2021.
298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2025, filed 6 Aug 2025.